Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus
Dr. Ivan Sanchez Fernandez discusses the main points from his paper on meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
don't worry if you don't have an account with us, we'll create one
[{"meta":{"author":"Neurology Minute","authorlink":""},"src":"http:\/\/traffic.libsyn.com\/neurologyminute\/May_14_2019_FAI_Higdon__Sanchez_Fernandez_NM_ver2.mp3?dest-id=1085030","thumb":{"src":"https:\/\/lystnimg.b-cdn.net\/podcastsnw-202109\/c33030-202f-27e9-f6fd80_800.png"},"title":"Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus","link":"javascript:;","id":"item-271875"}]
